Advertisement

Topics

NHS future ‘uncertain’ for Adcetris in ALCL

08:07 EDT 19 Jun 2017 | PharmaTimes

Cost regulators for NHS treatments in England and Wales say they are currently minded not to recommend Takeda’s Adcetris on the NHS for relapsed or refractory systemic anaplastic large cell lymphoma (ALCL), a cancer of the lymphatic system.

Original Article: NHS future ‘uncertain’ for Adcetris in ALCL

NEXT ARTICLE

More From BioPortfolio on "NHS future ‘uncertain’ for Adcetris in ALCL"

Advertisement
Quick Search
Advertisement
Advertisement